Back to search results

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

This study, called the Interprofessional Pharmacogenomics (IPGx) Registry and Repository, is collecting genetic and health information to help doctors choose the right medications for patients. It aims to understand how your genes affect how your body responds to medicines. The study will look at your medical history for one year before joining and for five years after. Success will be measured by tracking the frequency and nature of harmful side effects (Adverse Drug Reactions or ADRs) using the Naranjo Scale over five years. You may be able to join if you take five or more medications (including over-the-counter drugs, supplements, natural products, or cannabis products), or if you take blood pressure or depression medications, even if it's less than five. The current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 3000 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for five years after joining the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06726590

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

Recruiting
Not specifiedAges 18+Observational
Texas A&M University
~3,000 participants
Updated 2025-09-12 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency and nature of ADRs on the Naranjo Scale
Measured over 5 years

Conditions

Diabetes
Cholesterol
Cancer
Blood Pressure Disorders
Heart Disease
Respiratory Ilness
COPD
Adverse Drug Reaction (ADR)
Poly Pharmacy

Explore related trials

Adverse Drug ReactionCholesterolChronic Obstructive Pulmonary DiseaseDiabetes MellitusHeart DisorderHypertensionMalignant NeoplasmPolypharmacyRespiratory Illness

Where it's being run

1 sites across 1 states
Texas1

Who to contact

Kenneth S Ramos, MD, PhD
[email protected]
(713) 677-7440
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The study will invite patients who are eligible for PGX workup/PGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or
Individuals taking blood pressure or depression medications, even if less than five medications.
Ability to understand and give consent.
Able to consent to donate blood and/or urine samples and buccal swabs.
Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.
Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.
All genders.
Any age over 18 years.

Exclusion

Individuals admitted to hospice.
Declines to participate or interact with staff/share their medical status.
A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,
Individuals who are unable or unwilling to provide consent.
Unable to verbally communicate and comprehend English language

What this trial measures

  • Frequency and nature of ADRs on the Naranjo Scale5 years

    Patients will be referred to the Texas A\&M Interprofessional Pharmacogenomics Clinic (IPGx) by their primary care physicians. A physician or ambulatory pharmacist in the IPGx clinic or Family Care Clinic will obtain a complete medical history, physical examination, and validate the patient's current concomitant medication list at the IPGx during the office visit. Patient medical information would be input into the CSN, which functions as a computable EHR medical record analysis, evaluation of polypharmacy status, and monitoring of Adverse Drug Reactions using the Naranjo Scale questionnaire will be conducted for the duration of the study.